(Adds trial details in paragraph 2, background in paragraph 3 and share move in paragraph 4)
Nov 26 (Reuters) - PTC Therapeutics said on Tuesday it is discontinuing the development of its drug for a type of fatal neurodegenerative disease, as it did not meet the main goal in a mid-stage trial.
The company's drug, utreloxastat, failed to slow the progression of amyotrophic lateral sclerosis (ALS) in patients during the trial.
ALS affects 16,000 to 32,000 people in the United States, and has long eluded researchers looking for an effective treatment.
Shares of the New Jersey-based company fell 2.8% after the bell.
(Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。